Trust, Acceptance and Sufficiency: Law as a Barrier to, and Enabler of, Routine and Responsive Immunization including COVID-19A

  • Funded by Canadian Institutes of Health Research (CIHR), Health Canada
  • Total publications:19 publications

Grant number: 173056

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $182,955.56
  • Funder

    Canadian Institutes of Health Research (CIHR), Health Canada
  • Principle Investigator

    Pending
  • Research Location

    Canada, Americas
  • Lead Research Institution

    Dalhousie University
  • Research Category

    Policies for public health, disease control & community resilience

  • Research Subcategory

    Vaccine/Therapeutic/ treatment hesitancy

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Primary disease prevention through immunization is a global public health priority with clear economic and health and well-being benefits. However, there is growing recognition in Canada that vaccine uptake rates are not where they need to be for adequate control of vaccine preventable diseases. Importantly, these rates can be further eroded by unanticipated disruptive events such as a pandemic for which there is yet no vaccine (e.g., COVID-19). While control of COVID-19 will be more feasible once vaccine(s) become available, this will not be a simple decision federally or for the provinces and territories as it is highly probable that different types of COVID-19 vaccines will be available in Canada which differ as to safety and efficacy parameters, age targets, etc. While practice/program decisions need to be based on sound scientific evidence, legal considerations relevant to program design and delivery will frequently arise. For example, consider cases in which there are differences between manufacturer license recommendations and effective case- and conditions-sensitive use by and within programs. This project is a first step in gaining a better understanding of immunization, both routine and responsive i.e. in a pandemic, as a 'regulated space' . Laws may both help and may also hinder. The project will generate significant new insights into the content and scope of immunization governance frameworks ( laws and regulations) that exist across Canada, offering observations about their potential as barriers to, and enablers of, public health goals, with special attention to two issues that COVID-19 has already highlighted as problematic, namely the issues of mandates and vaccine injury compensation. The ultimate aim is to assist in identifying what might be done for Canada to perform better in this setting, taking into account its actions in response to COVID-19.

Publicationslinked via Europe PMC

Last Updated:38 minutes ago

View all publications at Europe PMC

An RNA-dependent and phase-separated active subnuclear compartment safeguards repressive chromatin domains.

PRAMEL7 and CUL2 decrease NuRD stability to establish ground-state pluripotency.

BAZ2A-RNA mediated association with TOP2A and KDM1A represses genes implicated in prostate cancer.

An equitable vaccine delivery system: Lessons from the COVID-19 vaccine rollout in Canada.

Public health communication in Canada during the COVID-19 pandemic.

Argonaute proteins regulate a specific network of genes through KLF4 in mouse embryonic stem cells.

Genome-wide maps of nucleolus interactions reveal distinct layers of repressive chromatin domains.

BAZ2A-mediated repression via H3K14ac-marked enhancers promotes prostate cancer stem cells.

Regulation and Roles of the Nucleolus in Embryonic Stem Cells: From Ribosome Biogenesis to Genome Organization.